Executive Team


President, Chief Executive Officer and Member of the Board

Dr. Coles joined Onyx in March 2008 as President, Chief Executive Officer, and a member of its board of directors. Prior to joining Onyx, he was President, Chief Executive Officer, and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2005, Dr. Coles was Senior Vice President of Commercial Operations at Vertex Pharmaceuticals Incorporated, which he joined in 2002. Beginning in 1996, he held a number of executive positions while at Bristol-Myers Squibb Company, including Senior Vice President of Strategy and Policy; Senior Vice President of Marketing and Medical Affairs, Neuroscience/Infectious Diseases/Dermatology; Vice President, Western Area Sales Cardiovascular and Metabolic Business Unit for U.S. Primary Care; and Vice President, Cardiovascular Global Marketing. From 1992 until 1996, Dr. Coles also held a number of positions of increasing responsibility at Merck & Co., Inc., including Vice President of the Hypertension and Heart Failure Business Group.

Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School. He earned an M.D. degree from Duke University, a master’s degree in public health from Harvard University, and an undergraduate degree from Johns Hopkins University. Dr. Coles currently serves as a trustee and member of the Executive Committee for the Johns Hopkins University Board of Trustees, as well as a member of the board of trustees for Johns Hopkins Medicine. Dr. Coles is also a member of the board of directors for Laboratory Corporation of America (LabCorp), as well as Campus Crest Communities, Inc., both NYSE traded companies. He is also a member of the board of the Biotechnology Industry Organization (BIO).


Executive Vice President, Corporate Affairs

Laura A. Brege joined Onyx in June 2006 as executive vice president and chief business officer. In that role, she oversaw the expansion of key corporate capabilities and strengthened Onyx’s financial position by significantly adding to its cash reserves. Ms. Brege assumed her role as Chief Operating Officer in October 2007 and her current position in January 2011. In her new role, Ms. Brege is responsible for the oversight of all external relationships including, medical & scientific affairs, government affairs and public affairs (formerly known as corporate communications & investor relations). During her tenure at the company she has been responsible for the oversight and growth of key functions including marketing & sales, finance, business development, legal affairs, human resources, compliance, and corporate communications & investor relations. Before joining Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm. Prior to Red Rock, she was the senior vice president and chief financial officer at COR Therapeutics. Earlier in her career, Ms. Brege served as vice president and chief financial officer at Flextronics and vice president and treasurer of The Cooper Companies. Ms. Brege earned her undergraduate degree from Ohio University and has an MBA from the University of Chicago. She serves on the boards of Acadia Pharmaceuticals, Inc., BayBio and The Ohio University Foundation.


Executive Vice President and Chief Financial Officer

Matthew K. Fust joined Onyx in January 2009 as executive vice president and chief financial officer. Mr. Fust is responsible for key functions including financial planning and analysis, accounting, tax and SEC reporting, as well as information technology, facilities and purchasing. Prior to joining Onyx, Mr. Fust was executive vice president and chief financial officer at Jazz Pharmaceuticals, which he joined in 2003. From 2002 until 2003, he was chief financial officer at Perlegen Sciences, a biotechnology company. Previously, he was senior vice president and chief financial officer at ALZA Corporation where he was an executive from 1996 until 2002. From 1991 until 1996, Mr. Fust was a manager in the healthcare strategy practice at Anderson Consulting. Mr. Fust earned an undergraduate degree in accounting from the University of Minnesota and an MBA from Stanford University. He serves as a member of the board of directors for Sunesis Pharmaceuticals.


Executive Vice President, Corporate Development and Strategy

Juergen Lasowski, Ph.D., executive vice president of corporate development and strategy, joined Onyx in May 2008 as senior vice president of corporate development. Recognizing the important role that corporate development has in shaping the company’s pipeline and strategic direction, Dr. Lasowski’s role was expanded to include corporate strategy in January 2011. While at Onyx, he has been the architect of many transactions, most notably the acquisition of Proteolix and the out-licensing of carfilzomib and ONX 0912 to Ono Pharmaceutical for Japan. Before joining Onyx, he was the senior vice president of corporate development at NPS Pharmaceuticals. Previously, Dr. Lasowski spent 17 years at Sanofi-Aventis and its predecessor companies in business development, strategy and marketing positions in the U.S., Japan and Germany. Dr. Lasowski earned his MBA from INSEAD, France, and his Ph.D. in organic chemistry from the University of Mainz, Germany.


Executive Vice President, Research & Development and Technical Operations

Ted W. Love, M.D. joined Onyx in January 2010 as Executive Vice President and Head of Research and Development. In January 2011 he assumed responsibility for technical operations. Prior to joining Onyx, Dr. Love was President, Chief Executive Officer and Chairman of the Board of Directors at Nuvelo, which he joined in 2001. Previously, he served as Senior Vice President of Development at Theravance, Inc. Earlier in his career; Dr. Love spent six years at Genentech, Inc. in a number of senior management positions in Medical Affairs and Product Development. As Vice President of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as Chairman of Genentech’s Product Development Committee. Dr. Love earned his undergraduate degree in molecular biology from Haverford College and his medical degree at Yale Medical School. Dr. Love completed his residency and fellowship training in internal medicine and cardiology at Harvard Medical School and Massachusetts General Hospital, where he later served on the faculty. He currently serves on the Board of Directors of Bio-Rad Laboratories, Inc., Affymax, Inc., Santarus, Inc., ARCA biopharma, Inc., and on the California Institute for Regenerative Medicine (CIRM) Independent Citizens’ Oversight Committee.


Senior Vice President, Global Human Resources

Kaye Foster-Cheek joined Onyx Pharmaceuticals in September 2010 as Senior Vice President, Global Human Resources. Ms. Foster-Cheek is responsible for all aspects of the human resource function at Onyx Pharmaceuticals, including staffing, recruiting, compensation and benefits, performance management, organizational learning and development, organizational structure and design, and employee relations. Prior to joining Onyx, Ms. Foster-Cheek was Vice President of Human Resources and Executive Committee Member at Johnson & Johnson where she was responsible for the human resources and talent management functions. Ms. Foster-Cheek began her career at Johnson & Johnson in May 2003, as Vice President, Human Resources for the Johnson & Johnson North American Consumer Products Companies. In March 2004, she was promoted to Vice President, Human Resources, for the Consumer & Personal Care Group, the position she held until assuming her role as Vice President of Human Resources in 2005. Prior to joining Johnson & Johnson, Ms. Foster-Cheek held several senior Human Resources executive positions with Pfizer Inc, and led the integration of both the Warner-Lambert and Pharmacia mergers for multiple countries. Ms. Foster-Cheek earned her undergraduate degree at Baruch College of the City University of New York and received an M.B.A. from Columbia University Graduate School of Business.


Senior Vice President, General Counsel

Suzanne M. Shema, J.D. joined Onyx in August 2009 as senior vice president, general counsel.  Prior to joining Onyx, Ms. Shema was senior vice president and general counsel of law and compliance at ZymoGenetics, which she joined in 2001.  Before ZymoGenetics, Ms. Shema served as general counsel at aQuantive, Inc.   She also served as associate general counsel at Research Corporation Technologies, Inc.  Prior to Research Corporation Technologies, Ms. Shema served as associate general counsel at NeoRx Corporation.  Earlier in her career, she served as an associate at the law firm of Seed and Berry.  Ms. Shema earned an undergraduate degree in chemistry from the University of Texas, a master’s degree in chemistry from the University of Washington and a J.D. from the University of Washington.


Vice President, Public Affairs

Julie Wood joined Onyx in May 2003 to manage all communications for the company. She has an extensive background in investor relations and corporate communications, with a particular emphasis on the life sciences. In her current role, Ms. Wood is responsible for overseeing investor relations, corporate communications, advocacy relations, media relations and internal communications. Prior to Onyx, Ms. Wood was senior director of investor relations and corporate communications at Caliper Technologies Corp. Ms. Wood has served in a similar capacity at Sangamo BioSciences and Chiron Corporation. She earned her undergraduate degree from Stanford University and has an MBA from Duke University.

Stock Quote (update every 15 minutes): As of 4:00pm - 5/20/2011

  • Symbol
  • Last
    43.71 +0.22
  • Open
  • High
  • Low
  • Volume